Clinical Trials

A major clinical trial setback for a promising liver disease drug leaves patients waiting and puts Bausch Health's future strategy under scrutiny.

A new strategic partnership aims to dismantle commercialization hurdles, promising faster access to life-saving therapies for rare disease patients.

Swedish biotech innovator Hansa Biopharma wins a top award for its life-saving transplant tech, facing a pivotal year with FDA review on the horizon.

PulseSight's first-in-class gene therapy for dry AMD completes its Phase I trial, offering a novel approach to a leading cause of vision loss.

With a $150M+ capital raise and a top cancer immunologist on board, the T1D Fund is making a strategic play to shift from managing T1D to curing it.

A novel cell therapy for Parkinson's earns a key FDA designation, signaling a potential paradigm shift from managing symptoms to reversing the disease.

Carrying the Alzheimer's gene, a longevity expert has turned himself into a public experiment, documenting his radical protocol to prevent the disease.

The world's top cancer center partners with IBA in a multi-million dollar deal to install three advanced Proteus®ONE systems, heralding a new era.

Crosswalk Therapeutics secures a key grant to develop a therapy targeting the debilitating skeletal disease in Morquio A, a challenge current treatments can't solve.

Equinox's new EQX ARC program partners with Oura and Function to offer hyper-personalized, data-driven training for women across all life stages.

The Korean biopharma giant is leveraging its biosimilar success to fund a major push into cutting-edge cancer therapies and advanced drug platforms.

Cogent Biosciences is set for a transformative year, eyeing three FDA submissions and a launch for its lead drug, with a deep pipeline to follow.

Promising new 96-week data shows Vir's therapy could redefine care for severe hepatitis delta, as its oncology pipeline and financial runway also advance.

As its single-dose glaucoma therapy nears trials, Diorasis adds a seasoned dealmaker to its board, signaling a strategic shift toward market entry.

A new alliance aims to advance KFRX06, a unique Parkinson's therapy that goes beyond a single target to potentially offer a more comprehensive treatment.

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

With $82M in funding and novel gene insertion technology, Averna Therapeutics is poised to make waves at the pivotal J.P. Morgan Healthcare Conference.

Biocytogen and Acepodia are expanding their partnership to create next-gen ADCs with two targets and two warheads, aiming to defeat drug-resistant cancers.

An expanded partnership aims to create next-gen cancer therapies by combining bispecific antibodies with two distinct drugs to overcome tumor resistance.

With blockbuster preliminary sales and rapid patient adoption, Liquidia's new inhaled therapy is challenging established players in the lung disease space.